Maravai LifeSciences (MRVI) investor relations material

Business overview and market position

• Provides critical solutions for mRNA, gene editing, cell and gene therapy, vaccines, and biologics manufacturing, serving the life sciences sector from discovery to commercialization.

• TriLink offers highly modified nucleic acids, enzymes, and proprietary mRNA technologies, supporting vaccine and therapeutic development.

• Cygnus delivers assays and analytical services for impurity detection in biotherapeutic manufacturing, with broad adoption in monoclonal antibodies and gene therapies.

• Customer base includes 96% of the top 25 global biopharma R&D spenders.

• New management team brings significant turnaround experience and industry expertise.

Financial performance and restructuring

• Achieved stabilization post-restructure, exceeding cost reduction targets by removing over $65M in costs.

• Returned to positive adjusted EBITDA in Q4 2025, with base revenue up 18% year-over-year and TriLink base up 25%.

• Anticipates $10–$20M annual revenue from COVID GMP CleanCap® starting in 2026.

• Focused on improving financial profile with opportunities for EBITDA margin expansion.

• Non-GAAP measures such as Adjusted EBITDA and Adjusted Net Loss are used to provide additional insight into performance.

Strategic priorities and growth initiatives

• Post-restructuring strategy centers on commercial execution, operational excellence, and R&D focus.

• Expanding mRNABuilder platform and customer base, with deeper engagement and broader product portfolio.

• Implemented automation and centralized operations for scalable improvements.

• Prioritizing high-return R&D opportunities at TriLink and Cygnus, with a robust pipeline of new products for 2026.

• Positioned for long-term, sustainable, profitable growth through strategic clarity and innovation.